138 related articles for article (PubMed ID: 23795724)
1. Enhancement of cisplatin-based TACE by a hemoglobin-based oxygen carrier in an orthotopic rat HCC model.
Liu XB; Cheng Q; Geng W; Ling CC; Liu Y; Ng KT; Yam JW; Guan XY; Lo CM; Man K
Artif Cells Nanomed Biotechnol; 2014 Aug; 42(4):229-36. PubMed ID: 23795724
[TBL] [Abstract][Full Text] [Related]
2. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
3. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
4. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
Tak E; Lee S; Lee J; Rashid MA; Kim YW; Park JH; Park WS; Shokat KM; Ha J; Kim SS
J Hepatol; 2011 Feb; 54(2):328-39. PubMed ID: 21056497
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma.
Ng KT; Yeung OW; Liu J; Li CX; Liu H; Liu XB; Qi X; Ma YY; Lam YF; Lau MY; Qiu WQ; Shiu HC; Lai MK; Lo CM; Man K
Int J Oncol; 2020 Oct; 57(4):956-966. PubMed ID: 32945373
[TBL] [Abstract][Full Text] [Related]
6. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Zhang G; Xiao Y; Tan J; Liu H; Fan W; Li J
J Transl Med; 2024 Jun; 22(1):543. PubMed ID: 38844930
[TBL] [Abstract][Full Text] [Related]
7. Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma.
Vandewynckel YP; Laukens D; Devisscher L; Bogaerts E; Paridaens A; Van den Bussche A; Raevens S; Verhelst X; Van Steenkiste C; Jonckx B; Libbrecht L; Geerts A; Carmeliet P; Van Vlierberghe H
BMC Cancer; 2016 Jan; 16():9. PubMed ID: 26753564
[TBL] [Abstract][Full Text] [Related]
8. Influence of PEG-conjugated hemoglobin on tumor oxygenation and response to chemotherapy.
Yu M; Han J; Dai M; Cui P; Li H; Liu Q; Xiu R
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(6):551-61. PubMed ID: 19065307
[TBL] [Abstract][Full Text] [Related]
9. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
[TBL] [Abstract][Full Text] [Related]
10. Synergy of Raddeanin A and cisplatin induced therapeutic effect enhancement in human hepatocellular carcinoma.
Li JN; Yu Y; Zhang YF; Li ZM; Cai GZ; Gong JY
Biochem Biophys Res Commun; 2017 Apr; 485(2):335-341. PubMed ID: 28219642
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
Asechi H; Hatano E; Nitta T; Tada M; Iwaisako K; Tamaki N; Nagata H; Narita M; Yanagida A; Ikai I; Uemoto S
Int J Oncol; 2010 Jul; 37(1):89-96. PubMed ID: 20514400
[TBL] [Abstract][Full Text] [Related]
12. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human heptocellular carcinomas.
Lee J
Arch Pharm Res; 2010 Sep; 33(9):1401-9. PubMed ID: 20945139
[TBL] [Abstract][Full Text] [Related]
13. VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells.
Zhou Z; Lu X; Zhu P; Zhu W; Mu X; Qu R; Li M
Biochem Biophys Res Commun; 2012 Apr; 420(2):336-42. PubMed ID: 22425983
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of MDR1 in PEG-conjugated hemoglobin solution combined cisplatin treatment in a tumor xenograft model.
Han J; Yu M; Dai M; Li H; Xiu R; Liu Q
Artif Cells Blood Substit Immobil Biotechnol; 2012 Aug; 40(4):239-44. PubMed ID: 22432540
[TBL] [Abstract][Full Text] [Related]
15. Effects of Diaspirin Crosslinked Hemoglobin (DCLHb) on microcirculation and local tissue pO2 of striated skin muscle following resuscitation from hemorrhagic shock.
Hungerer S; Nolte D; Botzlar A; Messmer K
Artif Cells Blood Substit Immobil Biotechnol; 2006; 34(5):455-71. PubMed ID: 16893810
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt.
Kang JW; Kim JH; Ko GY; Gwon DI; Yoon HK; Sung KB
Acta Radiol; 2012 Jun; 53(5):545-50. PubMed ID: 22547388
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB; Huang MS
Oncol Rep; 2011 Feb; 25(2):461-8. PubMed ID: 21152876
[TBL] [Abstract][Full Text] [Related]
18. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
Gaddameedhi S; Chatterjee S
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
[TBL] [Abstract][Full Text] [Related]
19. Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma.
Al-Rawashdeh FY; Scriven P; Cameron IC; Vergani PV; Wyld L
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1099-105. PubMed ID: 20177386
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization for hepatocellular carcinoma: significance of extrahepatic collateral supply.
Paul SB; Gamanagatti SR; Mukund A; Abbas SZ; Acharya SK
Indian J Cancer; 2011; 48(3):339-44. PubMed ID: 21921335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
